Lihui Lu

发表

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.

B. Ruggeri, T. Underiner, B. Dorsey, 2006, Blood.

Changes in the subcellular localization of the Brn4 gene product precede mesenchymal remodeling of the otic capsule

M. Lechner, D. Phippard, T. Kyin, 1998, Hearing Research.

BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia

Shuiyan Wu, Jian Pan, F. Fang, 2022, Journal of immunology research.

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).

A. Ghose, P. Dobrzanski, E. Bruckheimer, 2016, Journal of medicinal chemistry.

BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes

Shuiyan Wu, Jian Pan, F. Fang, 2022, Cancer biology & therapy.

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

A. Ghose, B. Ruggeri, K. Wells-Knecht, 2012, Journal of medicinal chemistry.

2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.

A. Ghose, B. Ruggeri, D. Gingrich, 2011, Journal of medicinal chemistry.

Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.

Andrew V. Anzalone, B. Ruggeri, T. Underiner, 2010, ACS medicinal chemistry letters.

Development of multiple cell-based assays for the detection of histone H3 Lys27 trimethylation (H3K27me3).

Haiching Ma, Jianghong Wu, J. Qian, 2013, Assay and drug development technologies.

Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.

B. Ruggeri, R. Haltiwanger, B. Dorsey, 2015, Bioorganic & medicinal chemistry letters.

Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.

K. Wells-Knecht, H. Breslin, B. Dorsey, 2012, Journal of medicinal chemistry.

CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers

G. Inghirami, B. Ruggeri, D. Gingrich, 2011, Molecular Cancer Therapeutics.

Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Andrew V. Anzalone, Jason P. Burke, B. Ruggeri, 2011, Bioorganic & medicinal chemistry letters.

ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.

A. Ghose, B. Ruggeri, J. T. Durkin, 2009, Biochemistry.

Targeted Mutagenesis of the POU-Domain GeneBrn4/Pou3f4 Causes Developmental Defects in the Inner Ear

J. Saunders, D. Phippard, E. Crenshaw, 1999, The Journal of Neuroscience.

BRD4 PROTAC Degradation Agent GNE-987 Inhibits Acute Myeloid Leukemia by Targeting Super Enhancers

Shuiyan Wu, Jian Pan, F. Fang, 2021 .

Inhibition of Receptor Interacting Protein Kinases Attenuates Cardiomyocyte Hypertrophy Induced by Palmitic Acid

Xiaoju Tang, Xiaojing Liu, Mingyue Zhao, 2016, Oxidative medicine and cellular longevity.

LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1

F. Fang, Yuanyuan Tian, Yanfang Tao, 2023, Cell death & disease.

Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.

R. Haltiwanger, B. Dorsey, T. Angeles, 2015, Bioorganic & medicinal chemistry letters.

A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells

Shuiyan Wu, Jian Pan, F. Fang, 2022, Pathology oncology research : POR.